Skip to content

Study · In vitro (cells) · 2011

7 results

Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10.

Martínez-Fuentes AJ, Molina M, Vázquez-Martínez R, Gahete MD, Jiménez-Reina L, Moreno-Fernández J, Benito-López P, Quintero A, de la Riva A, Diéguez C, Soto A, Leal-Cerro A and 7 more

Show all authors

Resmini E, Webb SM, Zatelli MC, degli Uberti EC, Malagón MM, Luque RM, Castaño JP

European journal of endocrinology17 Dec 2010Cited by 22 (Europe PMC)

PMID21169415 (opens in a new tab)DOI10.1530/eje-10-0905 (opens in a new tab)PepBankPUB-21169415
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    Cells from non-functioning pituitary adenomas did not respond to kisspeptin‑10 with a calcium increase.

    In plain wordsIn lab-grown cells from human non-functioning pituitary tumors, kisspeptin‑10 did not raise calcium inside the cells.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeIntracellular calcium response to kisspeptin-10 in non-functioning adenoma cells
    Study

    humann = 45

    dispersed pituitary adenoma cells in primary culture
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas cells derived from non-functioning pituitary adenomas (NFPA, n=45) did not respond.
    1 context sentence
    Summary · context
    Additionally, functionality of this system was assessed by treating dispersed pituitary adenoma cells in primary culture with kisspeptin-10 and evaluating intracellular calcium kinetics and apoptotic rate.
  2. 02LabIn vitro (cells)Activity measurement

    Kisspeptin‑10 increased intracellular calcium in individual cells from four of five GH-producing pituitary adenomas.

    In plain wordsIn lab-grown cells from human growth-hormone pituitary tumors, kisspeptin‑10 raised calcium inside the cells in four of five tumors.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseIntracellular calcium response to kisspeptin-10 in GH-producing adenoma cells
    Study

    humann = 5

    dispersed pituitary adenoma cells in primary culture
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Measurement of calcium kinetics revealed that kisspeptin-10 elicits a remarkable increase in [Ca(2+)](i) in individual cells from four out of the five GH-producing adenomas studied
    1 context sentence
    Summary · context
    Additionally, functionality of this system was assessed by treating dispersed pituitary adenoma cells in primary culture with kisspeptin-10 and evaluating intracellular calcium kinetics and apoptotic rate.
  3. 03LabIn vitro (cells)Efficacy outcome

    Kisspeptin‑10 treatment increased the apoptotic rate in cells derived from GH-producing pituitary adenomas.

    In plain wordsIn lab-grown cells from human growth-hormone pituitary tumors, kisspeptin‑10 raised the rate of cell death.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseApoptotic rate in GH-producing adenoma cells
    Study

    humann: not reported in source

    dispersed pituitary adenoma cells in primary culture
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, kisspeptin-10 treatment increased the apoptotic rate in cells derived from both GH-producing and NFPA.
    1 context sentence
    Summary · context
    Additionally, functionality of this system was assessed by treating dispersed pituitary adenoma cells in primary culture with kisspeptin-10 and evaluating intracellular calcium kinetics and apoptotic rate.
  4. 04LabIn vitro (cells)Efficacy outcome

    Kisspeptin‑10 treatment increased the apoptotic rate in cells derived from non-functioning pituitary adenomas.

    In plain wordsIn lab-grown cells from human non-functioning pituitary tumors, kisspeptin‑10 raised the rate of cell death.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseApoptotic rate in non-functioning adenoma cells
    Study

    humann: not reported in source

    dispersed pituitary adenoma cells in primary culture
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, kisspeptin-10 treatment increased the apoptotic rate in cells derived from both GH-producing and NFPA.
    1 context sentence
    Summary · context
    Additionally, functionality of this system was assessed by treating dispersed pituitary adenoma cells in primary culture with kisspeptin-10 and evaluating intracellular calcium kinetics and apoptotic rate.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 05LabEndogenous levelEx vivo tissueMechanism

    Both KISS1 and KISS1R were expressed in normal human pituitary.

    In plain wordsNormal human pituitary tissue carries the genes for the body's own kisspeptin and its receptor.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableKISS1 and KISS1R expression in normal pituitary
    Study

    humann: not reported in source

    normal and adenomatous human pituitary tissue
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Both KISS1 and KISS1R were expressed in normal pituitary
    1 context sentence
    Summary · context
    To explore this notion, expression levels of KISS1R and KISS1 were evaluated in normal and adenomatous pituitaries.

    This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.

  2. 06LabEndogenous levelEx vivo tissueMechanism

    Simultaneous KISS1 and KISS1R expression was frequently lost in human pituitary tumors compared with normal pituitary.

    In plain wordsHuman pituitary tumors often lost the joint activity of the genes for the body's own kisspeptin and its receptor.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseSimultaneous KISS1 and KISS1R expression in pituitary tumors
    Study

    humann: not reported in source

    normal and adenomatous human pituitary tissue
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    whereas this simultaneous expression was frequently lost in pituitary tumors
    1 context sentence
    Summary · context
    To explore this notion, expression levels of KISS1R and KISS1 were evaluated in normal and adenomatous pituitaries.

    This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.

  3. 07LabEndogenous levelEx vivo tissueMechanism

    Diverse patterns of KISS1 and KISS1R expression occurred in pituitary tumors and differed among adenoma types.

    In plain wordsThe activity of the body's own kisspeptin genes differed between types of human pituitary tumor.

    Peptide
    Kisspeptin-10
    Outcome
    MixedKISS1 and KISS1R expression patterns across adenoma types
    Study

    humann: not reported in source

    normal and adenomatous human pituitary tissue
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    where diverse patterns of KISS1/KISS1R expression were observed that differed among distinct types of pituitary adenomas.
    1 context sentence
    Summary · context
    To explore this notion, expression levels of KISS1R and KISS1 were evaluated in normal and adenomatous pituitaries.

    This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.